US Patent 11167049 Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
Patent 11167049 was granted and assigned to Molecular Insight Pharmaceuticals, Inc. on November, 2021 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 11167049 Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.